Daiichi Sankyo: Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at ASCO First presentation of phase 1 data from a cohort
United States Masashi Kawase Iane Krop Daiichi Sankyo Daiichi Sankyo Europe Gmb Patritumab Deruxtecan
Source: finanznachrichten.de